MX336979B - Combinacion farmaceutica antineuritica y composiciones. - Google Patents

Combinacion farmaceutica antineuritica y composiciones.

Info

Publication number
MX336979B
MX336979B MX2011014042A MX2011014042A MX336979B MX 336979 B MX336979 B MX 336979B MX 2011014042 A MX2011014042 A MX 2011014042A MX 2011014042 A MX2011014042 A MX 2011014042A MX 336979 B MX336979 B MX 336979B
Authority
MX
Mexico
Prior art keywords
compositions
antineuritic
pharmaceutical combination
combinations
antiepileptic
Prior art date
Application number
MX2011014042A
Other languages
English (en)
Other versions
MX2011014042A (es
Inventor
María Angélica Arzola Paniagua
Héctor Senosiain Arroyo
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48611941&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336979(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Priority to MX2011014042A priority Critical patent/MX336979B/es
Priority to CA2859487A priority patent/CA2859487C/en
Priority to ES201490063A priority patent/ES2525952B1/es
Priority to BR112014014774A priority patent/BR112014014774A2/pt
Priority to PE2014000973A priority patent/PE20141688A1/es
Priority to PCT/IB2012/057345 priority patent/WO2013088410A1/es
Priority to US14/365,988 priority patent/US20140323428A1/en
Priority to PL409542A priority patent/PL231163B1/pl
Publication of MX2011014042A publication Critical patent/MX2011014042A/es
Priority to CL2014001581A priority patent/CL2014001581A1/es
Priority to DO2014000134A priority patent/DOP2014000134A/es
Priority to CR20140283A priority patent/CR20140283A/es
Priority to NI201400058A priority patent/NI201400058A/es
Priority to GT201400115A priority patent/GT201400115A/es
Priority to CO14129791A priority patent/CO6990712A2/es
Publication of MX336979B publication Critical patent/MX336979B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a combinaciones farmacéuticas de dos antiepilépticos, así como combinaciones de un antiepiléptico, y vitaminas del complejo B, en donde los antiepilépticos se seleccionan de pregabalina y oxcarbazepina, y las vitaminas se seleccionan de vitamina Bi y vitamina 312. También se refiere a composiciones farmacéuticas que contienen dichas combinaciones y al uso de dichas composiciones para el tratamiento del dolor neuropático (DN).
MX2011014042A 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones. MX336979B (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.
US14/365,988 US20140323428A1 (en) 2011-12-16 2012-12-14 Antineuritic pharmaceutical combination and compositions
PCT/IB2012/057345 WO2013088410A1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones
PL409542A PL231163B1 (pl) 2011-12-16 2012-12-14 Kombinacja i kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu bólowi z powodu umiarkowanych do ciężkich neuralgii o różnorodnym umiejscowieniu
ES201490063A ES2525952B1 (es) 2011-12-16 2012-12-14 Combinación farmacéutica antineurítica y composiciones
BR112014014774A BR112014014774A2 (pt) 2011-12-16 2012-12-14 combinação farmacêutica antineurítica e composições
PE2014000973A PE20141688A1 (es) 2011-12-16 2012-12-14 Combinacion farmaceutica antineuritica y composiciones
CA2859487A CA2859487C (en) 2011-12-16 2012-12-14 Antineuritic pharmaceutical combination and compositions
CO14129791A CO6990712A2 (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineuritica y composiciones
CL2014001581A CL2014001581A1 (es) 2011-12-16 2014-06-16 Combinacion farmaceutica que comprende a) un antiepileptico seleccionado de pregabalina u oxcarbazepina y b) vitaminas seleccionadas de i) vitamina b12, ii) vitamina b1 y b12, con excepcion de metilcobalamina y benfotiamina; composicion farmaceutica; y su uso para tratar o prevenir el dolor moderado a severo; kit de partes.
GT201400115A GT201400115A (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineurítica y composición
DO2014000134A DOP2014000134A (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineuritica y composiciones
CR20140283A CR20140283A (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineuritica y composiciones
NI201400058A NI201400058A (es) 2011-12-16 2014-06-16 Combinación farmacéutica antineurítica y composiciones

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.

Publications (2)

Publication Number Publication Date
MX2011014042A MX2011014042A (es) 2013-06-17
MX336979B true MX336979B (es) 2016-02-09

Family

ID=48611941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011014042A MX336979B (es) 2011-12-16 2011-12-16 Combinacion farmaceutica antineuritica y composiciones.

Country Status (14)

Country Link
US (1) US20140323428A1 (es)
BR (1) BR112014014774A2 (es)
CA (1) CA2859487C (es)
CL (1) CL2014001581A1 (es)
CO (1) CO6990712A2 (es)
CR (1) CR20140283A (es)
DO (1) DOP2014000134A (es)
ES (1) ES2525952B1 (es)
GT (1) GT201400115A (es)
MX (1) MX336979B (es)
NI (1) NI201400058A (es)
PE (1) PE20141688A1 (es)
PL (1) PL231163B1 (es)
WO (1) WO2013088410A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2826470B1 (en) * 2013-07-19 2017-09-06 Arven Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of pregabalin
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070007276A (ko) * 2003-12-29 2007-01-15 제이슨 맥데빗 재발성 의학적 증상을 치료하기 위한 조성물 및 방법
ES2416723T3 (es) * 2007-10-09 2013-08-02 Merck Patent Gmbh Composiciones farmacéuticas que contienen benfotiamina y gabapentina
US8394759B2 (en) * 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes

Also Published As

Publication number Publication date
US20140323428A1 (en) 2014-10-30
CL2014001581A1 (es) 2014-09-26
DOP2014000134A (es) 2014-07-31
CO6990712A2 (es) 2014-07-10
CA2859487C (en) 2016-11-15
ES2525952B1 (es) 2015-10-05
CA2859487A1 (en) 2013-06-20
GT201400115A (es) 2017-07-27
PL409542A1 (pl) 2015-07-20
PL231163B1 (pl) 2019-01-31
PE20141688A1 (es) 2014-12-03
CR20140283A (es) 2015-03-11
WO2013088410A1 (es) 2013-06-20
MX2011014042A (es) 2013-06-17
ES2525952A1 (es) 2015-01-02
NI201400058A (es) 2014-12-22
BR112014014774A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MY192839A (en) Multi-supplement compositions
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
PH12016500094A1 (en) Autotaxin inhibitors
MY160456A (en) Benzodiazepine bromodomain inhibitor
WO2012170931A3 (en) Compounds that modulate intracellular calcium
PH12014501991B1 (en) Phenicol antibacterials
WO2012174158A3 (en) Administration of benzodiazepine
PH12014501032A1 (en) 2-thiopyrimidinones
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
MX2012013855A (es) Compuestos de oligobenzamida y su uso.
NZ735362A (en) Lipid compositions
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
WO2012170951A3 (en) Compounds that modulate intracellular calcium
EA201491426A1 (ru) Новые фармацевтические композиции, содержащие фосфатидилсерин и куркумин
MX2018007051A (es) Sistema de blanqueamiento de multiples componentes.
IN2015DN03132A (es)
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
HK1255345A1 (zh) 含有高濃度紫杉烷的用於口服給藥的藥物組合物
MX336979B (es) Combinacion farmaceutica antineuritica y composiciones.
EP3270883C0 (en) SCALABLE UNIT DOSAGE FORM OF A VITAMIN COMPOSITION FOR THE TREATMENT OF A DEFICIENCY IN LIPOSOLUBLE VITAMINS
MX356102B (es) Compuestos y métodos para tratar leucemia.
IN2012DE00826A (es)
MX2012014071A (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.

Legal Events

Date Code Title Description
FG Grant or registration